Companies by Therapeutic Condition

Psilocybin and other psychedelics have shown remarkable results for treatment-resistant depression, with several companies advancing Phase 2 and Phase 3 trials. The FDA has granted Breakthrough Therapy Designation to multiple compounds for depression.

MDMA-assisted therapy has shown transformative results for PTSD in clinical trials, with Phase 3 data showing 67% of participants no longer meeting PTSD criteria. Several companies are pursuing FDA approval and expanding access.

Anxiety disorders affect 40 million Americans, and psychedelic therapies are showing promise across generalized anxiety, social anxiety, and end-of-life anxiety. LSD, psilocybin, and MDMA are all in active trials.

Psychedelics show strong potential for breaking addiction cycles, with psilocybin demonstrating significant results for alcohol use disorder and ibogaine attracting substantial research funding for opioid addiction treatment.

Psilocybin and MDMA are being studied for anorexia nervosa, bulimia, and binge eating disorder, with early trials showing promise for conditions that have historically been difficult to treat.

Obsessive-compulsive disorder has shown early responses to psilocybin treatment, with the compound potentially disrupting rigid thought patterns. Small pilot studies have demonstrated sustained reductions in OCD symptoms.

Psychedelics including LSD and ketamine are being investigated for chronic pain syndromes, fibromyalgia, and phantom limb pain — conditions where current treatments often fall short.

Psilocybin-assisted therapy has shown profound effects on existential distress, anxiety, and depression in patients facing terminal illness. Landmark studies at NYU, Johns Hopkins, and other institutions have driven significant interest.